Volume 188 - Issue 11
Misleading advertising of PI-based drug information?*
Author: Jim R Stockigt
Med J Aust 2008; 188 (11): 679-680. || doi: 10.5694/j.1326-5377.2008.tb01839.x
Published online: 2 June 2008
Published online: 2 June 2008
* It should be noted that the question mark in the title was added at the Editor's discretion.
To the Editor: Why are those who market officially sanctioned information about pharmaceutical products not constrained by the advertising standards imposed on those who sell these products? Medicines Australia, which formulates a code of conduct for the pharmaceutical industry, imposes penalties, both financial and withdrawal of offending material, against misleading advertising of pharmaceutical products1,2 Why are similar standards not applied to advertising of information about these products?
There are well documented flaws in Australian drug information sources,2,3 such as MIMS (the Monthly Index of Medical Specialties), that are based on product information (PI) authorised by the Therapeutic Goods Administration (TGA). Some PI is decades out of date;2 bottlenecks in updating TGA-approved PI are apparent.4
In this light, advertising of PI-based information in the bimonthly MIMS summaries seems anomalous. The April–May 2008 bimonthly print edition of MIMS claims to present “100% pure knowledge”, and states that “you can count on MIMS being up-to-the-minute”, and that “MIMS is essential knowledge that Australian health professionals can trust”. Previous bimonthly MIMS summaries make similar assertions.
Until PI can be brought to an acceptable professional standard — a task that may be slow4 — it would seem appropriate to rein in misleading claims about PI widely used by health workers. Medicines Australia, or the National Prescribing Service, a government-funded body committed to “quality use of medicines”, could lead this initiative.
References
- Medicines Australia code of conduct: breaches. Australian Prescriber 2007; 30: 153-155.
- Stockigt JR. Barriers in the quest for quality drug information: salutary lessons from TGA-approved sources for thyroid-related medications. Med J Aust 2007; 186: 76-79. 0_i1091831
- Barriers in the quest for quality drug information: salutary lessons from TGA-approved sources for thyroid-related medications [matters arising]. Med J Aust 2007; 186: 483-485. 0_pgfId-1723658
- Dowden JS. Product information past perfect [editorial]. Med J Aust 2007; 186: 51-52. 0_CBBDHDFA
Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population
Hadar Mudrik-Zohar, Tim Cutfield, Susan Morpeth, Thomas Hills, Eamon Duffy, Laura J. Edwards, Allen C. Cheng, Steven Y. C. Tong
Birth prevalence, clinical sequelae, and management of congenital cytomegalovirus infections in Australia, 1999–2023: a national prospective study
Ece Egilmezer, Suzy M Teutsch, Carlos Nunez, Stuart T Hamilton, Adam W Bartlett, Pamela Palasanthiran, Elizabeth J Elliott, William D Rawlinson
Medication delivery and dispensing interval preferences of people who use antihypertensive medications in Australia: a survey study
Carissa Bonner, Michael A Fajardo, Rachael M Keast, Emily Atkins, Niamh Chapman, Kristie R Weir, Anthony Rodgers, Aletta E Schutte
Concurrent use of hormonal long‐acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013–2021
Michelle KY Chen, Adrian Lim, Deshan F Sebaratnam
Concurrent use of hormonal long‐acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013–2021
Aaron E Boyce, Tony Caccetta, Jo‐Ann See, Rosemary L Nixon AM